1. |
Lum BL, Torti FM. Adjuvant intravesical pharmacology for superficial bladder cancer. J Natl Cancer Inst, 1991, 83(10): 682-694.
|
2. |
Tolley DA, Hargreave TB, Smith PH, et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J, 1988, 296(6639): 1759-1761.
|
3. |
Melekos MD, Dauaher H, Fokaefs E, et al. Intravesical instillations of 4-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: results of a controlled prospective study. J Urol, 1992, 147(2): 371-375.
|
4. |
Oosterl inck W, Kurth KH, Schroder F, et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group. Randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol, 1993, 149(4): 749-752.
|
5. |
Martinez-Pineiro JA, Leon J, Martinez-Pineiro LJr. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol, 1990, 143(3): 502-506.
|
6. |
Carl L, Bo Johan N, Peter E, et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol, 1996, 156(2): 368-376.
|
7. |
Adrian PM, van der Meijden, Brausi M, et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Researchand Treatment of Cancer Genitourinary Group Randomized Phase III Trial. J Urol, 2001, 166: 476-481.
|
8. |
Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol, 1992, 147(3): 596-600.
|
9. |
Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol, 2006, 175(6): 2004-2010.
|
10. |
Higgins J, Green S, editors. Cochrane Handbook for SystematicReviews of Interventions 4.2.6[updated month year]. In: The Cochrane Library, Issue 4, 2006. Chichester: Wiley. Updated quarterly.
|
11. |
Montie JE. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. J Urol, 2006, 176(2): 507-508.
|
12. |
Di Stasi SM, Giannantoni A, Giuriol i A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Urologic Oncology, 2006, 24(3): 271-272.
|
13. |
Kamat AM, Col in PN. A combination of intravesical and BCG electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract Urol, 2006, 3(9): 472-473.
|
14. |
Rintala E, Jauhiainen K, Rajala P, et al. Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. J Urol, 1995, 154(6): 2050-2053.
|
15. |
Jauhiainen K, Rintala E. Superficial urinary bladder cancer. Results from the Finnbladder studies and a review on instillation treatments. Ann Chir Gynaecol Suppl, 1993, 206: 31-38.
|
16. |
Jauhiainen KE, Alfthan OS. Instillation therapy in superficial urinary bladder cancer. Finnbladder Group. Scand J Urol Nephrol Suppl, 1991, 138: 179-185.
|
17. |
Al i-El-Dein B, Sarhan O, Hinev A, et al Superficial bladder tumors: analysis of prognostic factors and construction of a predictive index. BJU International, 2003, 92: 393-399.
|
18. |
Witjes JA, Caris CTM, Mungan NA, et al. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol, 1998, 160(5): 1668-1671.
|
19. |
Rintala E, Jauhiainen K, Rajala P, et al. Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for caicinoma in situ of the bladder. J Urol, 1995, 154(6): 2050-2053.
|
20. |
Rintala E, Jauhiainen K, Kaasinen E, et al. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J Urol, 1996, 156(1): 56-59.
|
21. |
Al i-El-Dein B, Nabeeh A, Ismail EH, et al. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study. J Urol, 1999, 162(2): 339-342.
|
22. |
Bilen CY, Ozen H, Aki FT, et al. Clinical experience with BCG alone versus BCG plus epirubicin. Int J Urol, 2000, 7(6): 206-209.
|
23. |
Kaasinen E, Wijkstrom H, Malmstrom PU, et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol, 2003, 43(6): 637-645.
|
24. |
Di Stasi SM, Giannantoni A, Giuriol i A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. The lancet oncology, 2006, 7(1): 43-51.
|
25. |
Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy fou superficial bladder cancer. J Urol, 2003, 170: 964-969.
|
26. |
Wolf H, Melsen F, Pedersen SE, et al. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol, 1994, 157(suppl): 147.
|
27. |
Sarosdy MF. Management of high grade superficial bladder cancer: role of BCG. AUA Update Series, 1998, 17(12): 90.
|
28. |
Utz DC, Hanash K A, Farrow GM. The pl ight of the patient with carcinoma of the bladder. Trans Am Assoc Genitourin Surg, 1969, 61: 90-100.
|